Diseases

World Market for Addiction Disorders 2005-2012, The

New Horizons in High-Profile Dependency Markets

Publication Date	December 2005
Publisher	Spectra Intelligence
Product Type	Report
Pages	81
ISBN Number	not applicable
Product Code	SPE00002

Price

£1,100.00
approximately: $1,803 | €1,283

pdf

Order above formats by FAX

Examines the market for addiction pharmacotherapies currently estimated at US$2 billion but forecast to increase 41% CAGR to US$2.9 billion by 2012. Drivers of growth include increasing global prevalence of alcohol, narcotic, and nicotine dependencies and premarket pharmacotherapies to treat methamphetamine, phencyclidine, and gambling addictions. With over 30 drug candidates in the pipeline for addiction disorders, medical therapies for these highly prevalent difficult-to-treat conditions are on course for dynamic change. This report comments on strategic and commercial issues that may affect current product positioning and discusses key compounds such as naltrexone reformulations, nicotine replacement therapies, and novel vaccine therapies that have the potential to create new market sectors and become high-value products over the next decade. The report also provides insights into forthcoming market dynamics and product sales to 2012 to enable the reader to make assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Click here to see sample pages from this report (PDF format)

REPORT HIGHLIGHTS AND KEY FINDINGS

The current market for addiction disorders is valued at US$2 billion, which is forecast to increase 41% CAGR to US$2.9 billion by 2012

Critical analysis of alcohol, cocaine, opiate, and nicotine addictions

Review of epidemiological, aetiological, and demographic data for addiction disorders

Analysis of over 10 key marketed products and inclusion of 34 R&D candidates identified in preclinical to clinical stages of development for addiction disorders

Sales estimates (US$) to 2012 for major therapy areas

Strategic insights for life-cycle optimization and product development

Critical evaluation of leading addiction pharmacotherapies

Emerging markets identified and sector analysis

Trend analysis of industry events and activities over past 2 years

Detailed R&D themes and clusters by addiction area

Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)

High revenue-yielding prospects identified with projected sales estimations

R&D pipeline positioning for novel candidates

Market insights for product development and drug promotion

WHAT CAN I LEARN FROM THIS REPORT?

· Which addiction therapies are the current and potential future market leaders
· Insights into the demographics and aetiology of addiction disorders
· How companies are reformulating products for addiction indications
· Which premarket addiction pharmacotherapies are identified as high-value products
· Which companies are developing drugs for addiction disorders
· Sales predictions to 2012 for addiction pharmacotherapies
· What the likely impact of pipeline products will be on value growth of the addiction market over the next decade
· Which addiction subsectors could be niche market opportunities
· What the future outlook holds for addiction pharmacotherapies
· Insight into R&D trends for alcohol, cocaine, opiate, and nicotine addictions
· Which molecules and compounds are main R&D clusters for dependency disorders
· Which of the pipeline candidates are top prospects in the addiction market over the next
decade and to 2020
Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered…

REASONS TO PURCHASE THIS REPORT

· Detailed survey and analysis of the current and future global addiction disorder market
· Comprehensive update on key marketed products indicated for alcohol, opiate, and nicotine dependency disorders
· Review of epidemiological, demographic, aetiological, and therapeutic data associated with addiction disorders
· Market analysis and insight of key addiction pharmacotherapies and pipelines
· Market value predictions of individual marketed products to 2012
· Insight and trend analysis of pipeline products for addiction disorders
· Review of promising pipeline products and potential market opportunities
· Insight into potential high-revenue earning addiction pharmacotherapies
· Illustrates unmet needs of current pharmacotherapies to treat addictions and underserved subsectors of addiction disorders
· Provides extensive coverage of the R&D pipeline for addiction disorders
· Illustrates research themes and clusters for addiction candidates differentiated by mechanism of action and efficacy
· Provides leads for potential licensing opportunities

COMPANIES MENTIONED IN REPORT

ACRUX, ALKERMES, ALPHARMA, ASTRAZENECA, BIOTIE THERAPIES, BRISTOL-MYERS SQUIBB, BRITANNIA PHARMACEUTICALS, CATALYST PHARMA, CEPHALON, COLLEGIUM PHARMACEUTICALS, DRUG ABUSE SCIENCES, FOREST LABORATORIES, GLAXOSMITHKLINE, INTERVEXION THERAPEUTICS, LIPHA, MERCK, NABI PHARMACEUTICALS, NOVARTIS, PFIZER, SANOFI-AVENTIS, SCHERING-PLOUGH, SOMAXON PHARMACEUTICALS, TARGACEPT, TITAN PHARMACEUTICALS, XENOVA,

List of Tables

List of Figures

Executive Summary

Objectives of the Report

Research Methodology

Chapter 1 Introduction to Addiction Disorders

Addiction Disorders
Incidence of Addiction Disorders
Neurobiological Basis of Addiction
Treatment Options

Chapter 2 The Addiction Pharmacotherapy Market

Addictions
Market Overview for Addiction Disorders
Market Forecasts by Therapeutic Area
Alcohol Addiction
Narcotic Addiction
Tobacco Addiction
Market Forecasts for Addiction Disorders
Market Analysis of Drugs to Treat Addiction Disorders
Alcohol Addiction
Alcohol Addiction Pharmacotherapies
Acamprosate (Campral) - Merck/Forest Laboratories
Mechanisms of Action/Efficacy
Sales Estimates for Campral
Product Line Extension Possibilities
Disulfiram (Antabuse) - Alpharma
Mechanism of Action/Efficacy
Sales Estimates for Disulfiram
Naltrexone Hydrochlride
Mechanisms of Action/Efficacy
Reformulation - Vivitrex, Alkermes/Cephalon
Sales Estimates for Naltrexone
Pipeline Focus
Naltrexone Depot - Drug Abuse Sciences, France
Nalmefene - BioTie Therapies, Finland
Alcohol Addiction - Market Insights and Future Considerations
Narcotic Addiction Pharmacotherapeutics
Cocaine Addiction
Mechanisms of Action of Cocaine
Future Therapeutics for Cocaine Addiction
Vaccine Therapy Focus - Xenova
COC-AB/DAS-431 - Drug Abuse Sciences
Opiate Addiction
Drug Substitute Therapies
Subutex/Subroxone (Buprenorphine) - Schering-Plough/Reckitt Benckiser
Mechanisms of Action/Efficacy
Reformulation
Sales Estimates
Methadone
Mechanisms of Action/Efficacy
Sales Estimates
Drugs to Control Opiate Withdrawal Symptoms
Brittofex (Lofexidine) - Britannia Pharmaceuticals
Mechanisms of Action/Efficacy
Sales Estimates
Naltrexone
Potential Reformulation
Future Drugs to Treat Opiate Addiction
Probuphine - Titan Pharmaceuticals
Buprenorphine Depot - Drug Abuse Sciences
Narcotic Addiction - Market Insights and Future Considerations
Emerging Drug Addiction Focus
Methamphetamine/Phencyclidine Abuse and Dependency
InterveXion Therapeutics
Outlook for Pharmacotherapeutic Markets Related to Alcohol and Substance Abuse
Nicotine Addiction
Prevalence and Mortality Statistics
Nicotine - Mechanism of Action
Nicotine Dependency and Smoking Cessation
Smoking and Health Consequences
Healthcare Costs of Smoking Addiction
Nicotine Addiction Pharmacotherapeutics
Market Analysis of Smoking Cessation Pharmacotherapeutics
Nicotine Replacement Therapies
Nicorette/Nicotrol - Pfizer
Sales Estimates
NiQuitin/NicoDerm/Nicorette/Nicabate - GlaxoSmithKline
Sales Estimates
Nicotinell/Habitrol - Novartis
Sales Estimates
Other Smoking Cessation Pharmacotherapies
Zyban (Bupropion) - GlaxoSmithKline
Sales Estimates
Future Drugs to Treat Nicotine Addiction
Late-Stage Development Product Focus
Rimonabant (Acomplia) - Sanofi-Aventis
Varenicline - Pfizer
Vaccine Focus
NicVAX - Nabi Biopharmaceuticals
TA-NIC - Xenova
Nicotine Addiction - Market Insights and Future Considerations
Drugs in the Pipe

Chapter 3 Drugs in Research and Development

Addiction Disorders: Drugs in Research and Development
Research and Development Overview
Gambling Addiction - An Emerging Research and Development Area
Nalmefene - Somaxon Pharmaceuticals

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining

Market Analysis and Therapy Forecasting
Therapy Area Forecasts
Comparative Analysis: Addiction Pharmacotherapies
Prospect Mining
Addiction Disorder Pharmacotherapy Prospects
Therapy Area Forecasts 2012 and 2020

Chapter 5 Report Synopsis

Addictions - Key Data Points
Reference Sources

List of Tables

Table 1.1 Neurotransmitter Systems Associated with Addiction
Table 1.2 Drugs of Abuse and their Associations with Neurotransmitter Systems
Table 2.1 Estimated Global Sales (US$) and Annual Growth (%) of Key Drugs to Treat Addictions, 2004-
Table 2.2 Physiological Consequences of the Disulfiram-Alcohol Reaction29 Table 2.3 Estimated Sales (US$) and Annual Growth (%) of Smoking Cessation Therapies, 2004-2012 Table 2.4 Drugs in Development for Nicotine Addiction, 2005 (partial) 57 Table 3.1 Drugs in Development for Alcohol and Narcotic Addictions, 2005
Table 3.2 Drugs in Development for Nicotine Addiction, 2005
Table 4.1 Estimated Global Sales (US$) and Growth Rate (%) for Addiction Pharmacotherapies, 2004-
Table 4.2 Therapy Area Forecasts for the World Addiction Disorder Market, 2012 & 2020 (US$)

List of Figures

Figure 1.1 Prevalence of Alcohol, Smoking, and Illicit Drug Abuse in UK and US Populations, 2002-
Figure 2.1 Estimated Sales (US$) of Addiction Drugs Segmented by Therapeutic Area, 2004-
Figure 2.3 Estimated Global Sales (US$) of Leading Addiction Drugs by Therapy Area, 252005 &
Figure 4.1 Addiction Pharmacotherapy Market Forecasts, 2005 & 2012 (US$)
Figure 4.2 Comparative Analysis of Leading Addiction Pharmacotherapies, 2004-2012 (US$) Figure 4.3 Key Addiction Disorder Drug Prospects, 2005